The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nov 8, 2023 | Thorell Marella | Chief Financial Officer | Sell(S) | 2K | $0.33 | $598 |
| Nov 8, 2023 | Gill Simba | President & CEO, Director | Sell(S) | 172 | $0.33 | $57 |
| Nov 8, 2023 | McHale Duncan | Chief Medical Officer | Sell(S) | 3K | $0.33 | $1K |
| Nov 8, 2023 | Bodmer Mark | CSO, President of R&D | Sell(S) | 3K | $0.33 | $1K |
| Nov 7, 2023 | Thorell Marella | Chief Financial Officer | Option exercise(M) | 7K | — | — |
| Nov 7, 2023 | Thorell Marella | Chief Financial Officer | Option exercise(M) | 7K | — | $0 |
| Nov 7, 2023 | Gill Simba | President & CEO, Director | Option exercise(M) | 1K | — | — |
| Nov 7, 2023 | Gill Simba | President & CEO, Director | Option exercise(M) | 1K | — | $0 |
| Nov 7, 2023 | McHale Duncan | Chief Medical Officer | Option exercise(M) | 7K | — | — |
| Nov 7, 2023 | McHale Duncan | Chief Medical Officer | Option exercise(M) | 7K | — | $0 |
| Nov 7, 2023 | Bodmer Mark | CSO, President of R&D | Option exercise(M) | 7K | — | — |
| Nov 7, 2023 | Bodmer Mark | CSO, President of R&D | Option exercise(M) | 7K | — | $0 |
| Nov 2, 2023 | Thorell Marella | Chief Financial Officer | Sell(S) | 4K | $0.33 | $1K |
| Nov 2, 2023 | McHale Duncan | Chief Medical Officer | Sell(S) | 7K | $0.33 | $2K |
| Nov 2, 2023 | Bodmer Mark | CSO, President of R&D | Sell(S) | 7K | $0.33 | $2K |
| Nov 1, 2023 | Thorell Marella | Chief Financial Officer | Option exercise(M) | 13K | — | — |
| Nov 1, 2023 | Thorell Marella | Chief Financial Officer | Option exercise(M) | 13K | — | $0 |
| Nov 1, 2023 | McHale Duncan | Chief Medical Officer | Option exercise(M) | 13K | — | — |
| Nov 1, 2023 | McHale Duncan | Chief Medical Officer | Option exercise(M) | 13K | — | $0 |
| Nov 1, 2023 | Bodmer Mark | CSO, President of R&D | Option exercise(M) | 13K | — | — |
| Nov 1, 2023 | Bodmer Mark | CSO, President of R&D | Option exercise(M) | 13K | — | $0 |
| Sep 28, 2023 | Gill Simba | President & CEO, Director | Sell(S) | 2K | $3.94 | $8K |
| Sep 27, 2023 | Gill Simba | President & CEO, Director | Option exercise(M) | 15K | — | — |
| Sep 27, 2023 | Gill Simba | President & CEO, Director | Option exercise(M) | 15K | — | $0 |
| Sep 27, 2023 | Gill Simba | President & CEO, Director | Grant(A) | 60K | — | $0 |
| Sep 11, 2023 | McHale Duncan | Chief Medical Officer | Grant(A) | 38K | — | $0 |
| Sep 11, 2023 | Thorell Marella | Chief Financial Officer | Grant(A) | 38K | — | $0 |
| Sep 11, 2023 | Bodmer Mark | CSO, President of R&D | Grant(A) | 38K | — | $0 |
| Aug 8, 2023 | Thorell Marella | Chief Financial Officer | Sell(S) | 2K | $9.51 | $19K |
| Aug 8, 2023 | McHale Duncan | Chief Medical Officer | Sell(S) | 3K | $9.51 | $33K |
| Aug 8, 2023 | Gill Simba | President & CEO, Director | Sell(S) | 342 | $9.51 | $3K |
| Aug 8, 2023 | Bodmer Mark | CSO, President of R&D | Sell(S) | 3K | $9.51 | $30K |
| Aug 7, 2023 | Thorell Marella | Chief Financial Officer | Option exercise(M) | 7K | — | — |
| Aug 7, 2023 | Thorell Marella | Chief Financial Officer | Option exercise(M) | 7K | — | $0 |
| Aug 7, 2023 | McHale Duncan | Chief Medical Officer | Option exercise(M) | 7K | — | — |
| Aug 7, 2023 | McHale Duncan | Chief Medical Officer | Option exercise(M) | 7K | — | $0 |
| Aug 7, 2023 | Gill Simba | President & CEO, Director | Option exercise(M) | 1K | — | — |
| Aug 7, 2023 | Gill Simba | President & CEO, Director | Option exercise(M) | 1K | — | $0 |
| Aug 7, 2023 | Bodmer Mark | CSO, President of R&D | Option exercise(M) | 7K | — | — |
| Aug 7, 2023 | Bodmer Mark | CSO, President of R&D | Option exercise(M) | 7K | — | $0 |
| Jul 11, 2023 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | Buy(P) | 1.1M | $2.31 | $2.5M |
| Jul 11, 2023 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | Buy(P) | 3.2M | $2.31 | $7.5M |
| Jul 11, 2023 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | Buy(P) | 1.1M | $2.31 | $2.5M |
| Jul 11, 2023 | Moore Jeffrey R. | Director | Grant(A) | 2K | — | $0 |
| Jul 11, 2023 | Reynolds Alexander C | Director | Grant(A) | 2K | — | $0 |
| Jun 8, 2023 | Gill Simba | President & CEO, Director | Grant(A) | 1.0M | — | $0 |
| Jun 8, 2023 | Rosiello Robert L. | Director | Grant(A) | 30K | — | $0 |
| Jun 8, 2023 | Andres Juan | Director | Grant(A) | 20K | — | $0 |
| Jun 8, 2023 | Melas Kyriazi Theo | Director | Grant(A) | 20K | — | $0 |
| Jun 8, 2023 | McInnes Iain B. | Director | Grant(A) | 20K | — | $0 |
| Jun 8, 2023 | McHugh Julie | Director | Grant(A) | 20K | — | $0 |
| Jun 8, 2023 | Hohneker John | Director | Grant(A) | 20K | — | $0 |
| Jun 8, 2023 | Gutierrez-Ramos Jose-Carlos | Director | Grant(A) | 20K | — | $0 |
| Jun 8, 2023 | Williams Tonya | Director | Grant(A) | 20K | — | $0 |
| May 23, 2023 | Bodmer Mark | CSO, President of R&D | Sell(S) | 23K | $0.14 | $3K |
| May 8, 2023 | Gill Simba | President & CEO, Director | Sell(S) | 4K | $0.13 | $460 |
| May 8, 2023 | Thorell Marella | Chief Financial Officer | Sell(S) | 39K | $0.13 | $5K |
| May 8, 2023 | Bodmer Mark | CSO, President of R&D | Sell(S) | 68K | $0.13 | $9K |
| May 8, 2023 | McHale Duncan | Chief Medical Officer | Sell(S) | 67K | $0.13 | $9K |
| May 7, 2023 | McHale Duncan | Chief Medical Officer | Option exercise(M) | 130K | — | — |
| May 7, 2023 | McHale Duncan | Chief Medical Officer | Option exercise(M) | 130K | — | $0 |
| May 7, 2023 | Bodmer Mark | CSO, President of R&D | Option exercise(M) | 133K | — | — |
| May 7, 2023 | Bodmer Mark | CSO, President of R&D | Option exercise(M) | 133K | — | $0 |
| May 7, 2023 | Thorell Marella | Chief Financial Officer | Option exercise(M) | 130K | — | — |
| May 7, 2023 | Thorell Marella | Chief Financial Officer | Option exercise(M) | 130K | — | $0 |
| May 7, 2023 | Gill Simba | President & CEO, Director | Option exercise(M) | 23K | — | $0 |
| Apr 14, 2023 | Rosiello Robert L. | Director | Grant(A) | 40K | — | $0 |
| Feb 7, 2023 | Thorell Marella | Chief Financial Officer | Grant(A) | 520K | — | $0 |
| Feb 7, 2023 | McHale Duncan | Chief Medical Officer | Grant(A) | 520K | — | $0 |
| Feb 7, 2023 | Bodmer Mark | CSO, President of R&D | Grant(A) | 530K | — | $0 |
| Feb 7, 2023 | Gill Simba | President & CEO, Director | Grant(A) | 1.1M | — | $0 |
| Feb 7, 2023 | Gill Simba | President & CEO, Director | Grant(A) | 375K | — | $0 |
| Jan 31, 2023 | Plinio Mark D. | Chief Commercial Officer | Grant(A) | 1K | $0.88 | $1K |
| Jan 23, 2023 | Carriere Stephen J | Principal Accounting Officer | Sell(S) | 151 | $1.06 | $160 |
| Jan 19, 2023 | Carriere Stephen J | Principal Accounting Officer | Option exercise(M) | 354 | — | — |
| Jan 19, 2023 | Carriere Stephen J | Principal Accounting Officer | Option exercise(M) | 354 | — | $0 |
| Sep 1, 2022 | Thorell Marella | Chief Financial Officer | Grant(A) | 440K | — | $0 |
| Jul 29, 2022 | Plinio Mark D. | Chief Commercial Officer | Grant(A) | 1K | $1.79 | $2K |
| Jul 19, 2022 | Zung Jonathan B. | Chief Development Officer | Grant(A) | 115K | — | $0 |
| Jul 19, 2022 | Char Daniel | General Counsel | Grant(A) | 40K | — | $0 |
| Jun 30, 2022 | Epstein David R | Director | Option exercise(M) | 3K | — | $0 |
| Jun 30, 2022 | Epstein David R | Director | Option exercise(M) | 2K | — | $0 |
| Jun 30, 2022 | Epstein David R | Director | Option exercise(M) | 3K | — | $0 |
| Jun 30, 2022 | Epstein David R | Director | Option exercise(M) | 2K | — | $0 |
| Jun 10, 2022 | Darzi Lord Ara | Director | Grant(A) | 30K | — | $0 |
| Jun 10, 2022 | Epstein David R | Director | Grant(A) | 20K | — | $0 |
| Jun 9, 2022 | Andres Juan | Director | Grant(A) | 20K | — | $0 |
| Jun 9, 2022 | Darzi Lord Ara | Director | Grant(A) | 20K | — | $0 |
| Jun 9, 2022 | Hohneker John | Director | Grant(A) | 20K | — | $0 |
| Jun 9, 2022 | McHugh Julie | Director | Grant(A) | 20K | — | $0 |
| Jun 9, 2022 | McInnes Iain B. | Director | Grant(A) | 20K | — | $0 |
| Jun 9, 2022 | Melas Kyriazi Theo | Director | Grant(A) | 20K | — | $0 |
| May 31, 2022 | Epstein David R | Director | Option exercise(M) | 3K | — | $0 |
| May 31, 2022 | Epstein David R | Director | Option exercise(M) | 2K | — | $0 |
| May 31, 2022 | Epstein David R | Director | Option exercise(M) | 3K | — | $0 |
| May 31, 2022 | Epstein David R | Director | Option exercise(M) | 2K | — | $0 |
| May 27, 2022 | Flagship Ventures Fund IV-Rx, L.P. | 10% Owner | Buy(P) | 6.8M | $1.46 | $10.0M |
| May 27, 2022 | Flagship Ventures Fund IV-Rx, L.P. | 10% Owner | Buy(P) | 1.1M | $1.46 | $1.6M |
| May 27, 2022 | Flagship Ventures Fund IV-Rx, L.P. | 10% Owner | Buy(P) | 1.4M | $1.46 | $2.0M |
| May 27, 2022 | Flagship Ventures Fund IV-Rx, L.P. | 10% Owner | Buy(P) | 13.7M | $1.46 | $20.0M |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).